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The outcomes of children with congenital hemolytic anemia (CHA) undergoing total splenectomy (TS) or
partial splenectomy (PS) remain unclear. In this study, we collected data from 100 children with CHA who
underwent TS or PS from 2005 to 2013 at 16 sites in the Splenectomy in Congenital Hemolytic Anemia
(SICHA) consortium using a patient registry. We analyzed demographics and baseline clinical status,
operative details, and outcomes at 4, 24, and 52 weeks after surgery. Results were summarized as
hematologic outcomes, short-term adverse events (AEs) (30 days after surgery), and long-term AEs (31–
365 days after surgery). For children with hereditary spherocytosis, after surgery there was an increase in
hemoglobin (baseline 10.16 1.8 g/dl, 52 week 12.86 1.6 g/dl; mean6SD), decrease in reticulocyte and
bilirubin as well as control of symptoms. Children with sickle cell disease had control of clinical symptoms
after surgery, but had no change in hematologic parameters. There was an 11% rate of short-term AEs and
11% rate of long-term AEs. As we accumulate more subjects and longer follow-up, use of a patient registry
should enhance our capacity for clinical trials and engage all stakeholders in the decision-making process.
Am. J. Hematol. 90:187–192, 2015. VC 2014 Wiley Periodicals, Inc.
 Introduction
For severely affected children with congenital hemolytic anemia (CHA), a splenectomy can control hemolysis and limit sequestration crises [1].
However, the risks associated with total splenectomy (TS) such as sepsis, thrombosis, or pulmonary hypertension have led to increasing interest in
partial splenectomy (PS). A PS is designed to remove enough spleen to gain the desired hematological outcome while preserving splenic function
[1–4]. Although PS has been increasingly used for children with CHA, a prospective clinical trial comparing surgical therapies or surgical versus
medical therapies has not been done [3].
Recent health care initiatives have demonstrated the value of evidence-based practices based on large clinical datasets [5,6]. However, the use of
standard datasets for the study of surgical procedures and less common conditions is difficult, as these sets often do not record outcomes consid-
ered most important by clinicians and families [3,7,8]. In addition, research on spleen surgery in CHA is challenged by the heterogeneity of dis-
eases, small number of subjects, variations in technique, and inconsistent use of standardized data [3]. In these settings, a patient registry is a
powerful tool to collect data to guide clinical therapies.
To improve the care of children with CHA, we formed SICHA (Splenectomy in Congenital Hemolytic Anemia), a research consortium of pedi-
atric surgeons and hematologists at 16 sites across North America. To help families and clinicians understand the outcomes of spleen surgery for
CHA and to support the development of clinical trials, our consortium developed a web-based patient registry to collect standardized data for
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children with CHA undergoing TS or PS. The goal of this report is to
describe the outcomes for first 100 children in this registry over 1
year of follow-up. The secondary goal of this report is to assess data
quality in this registry.
 Methods
Registry design. To collect outcomes of children undergoing PS or TS, we cre-
ated a web-based registry using the Research Electronic Data Capture (REDCap)
platform, which is an open-source application for clinical research used by over
1,000 partners in the National Institutes of Health Clinical and Translational Sci-
ence Awards consortium [9]. For registry design, all site investigators first identified
important issues for a family and clinician considering spleen surgery, based on our
consortium’s previous comparative effectiveness review [3]. These concerns include
the need use of standardized data and definitions of all outcomes, analyses of dis-
ease type, and need for multicenter study.
Given these goals, we constructed a data dictionary to record important varia-
bles, which were agreed upon by all site investigators. Our registry incorporated
principles as described by the Agency for Health Care Research and Quality,
including the a priori identification of clinical questions, a web-based interface for
data entry, and use of established data standards [10]. All site research staff under-
went training via a webinar, and we developed a Manual of Procedures (MOP) to
ensure consistent practices across sites.
Subject enrollment. Children 2–17 years of age were eligible if they had a diag-
nosis of a CHA and underwent TS or PS at a SICHA site between 2005 and 2013
(see Appendix for site roster). Diagnoses included hereditary spherocytosis (HS),
sickle cell disease (SCD, including hemoglobin SS, SC, S-beta thalassemia), or other
type of CHA. All diseases were defined using standard clinical criteria, including
family history, laboratory analysis, or genetic analysis as appropriate [3]. Other
indications for splenectomy, such as trauma or idiopathic thrombocytopenia pur-
pura were excluded.
Each site’s Institutional Review Board (IRB) approved this study, and each site
retained all identifying information. If a family chose to participate, staff obtained
written informed consent from the parents or guardians. As only de-identified data
were collected centrally into the registry, the registry was designated as exempt
from IRB review. A Data Use Agreement was executed between each site and the
central coordinating center to enhance data exchange.
Data were collected prospectively from 76 children from 2008 to 2014 and retrospec-
tively from 24 children from 2005 to 2008. There were eight eligible children reported
to the central coordinating center whose parents declined enrollment, although the total
number of eligible children who were not enrolled was not collected. To test feasibility
of this registry, we pilot tested it at a single site and previously reported these findings
in 24 children with SCD [11]. Based on this pilot experience, we eliminated extraneous
variables, refined technical aspects of the data entry, and expanded inclusion to multiple
types of CHA prior to rollout as a multicenter registry.
As an observational registry, this study did not dictate any clinical care, includ-
ing the choice between TS and PS, use of laparoscopy or laparotomy, specific labo-
ratory testing, or use of concurrent surgical procedures, although all of these
outcomes were collected. For children undergoing partial splenectomy, we encour-
aged maintenance of 10–20% of normal splenic volume, based on previous clinical
and laboratory studies [3,12–14].
Data abstraction. We collected demographics and clinical status at baseline,
operative data, and outcomes at 4, 24, and 52 weeks after surgery. Data were col-
lected from medical records and entered into a web-based case report form (CRF)
at each site by a research assistant. Baseline data was obtained from values within 4
weeks prior to surgery; four-week outcomes within 2–8 weeks after surgery, 24-
week outcomes within 16–32 weeks, and 52-week outcomes within 48–56 weeks. In
cases of multiple data within these time frames, the data closest to the time point
were recorded. Laboratory values prior to preoperative transfusions were used as
baseline data.
We recorded 68 variables, including demographics, disease, indications for sur-
gery, clinical, laboratory and imaging data, and use of laparoscopy (see Supporting
Information Data 1 for variable list). We used established clinical and data stand-
ards for outcome definitions (see Supporting Information Data 2).
Adverse events (AEs) included infection (including type), acute chest syndrome
(ACS, for SCD patients only), thrombotic events, reoperation, and death (see
Appendix 2 for definition of AEs). For children undergoing PS, we collected base-
line and postoperative measurements of the spleen size using ultrasound, and calcu-
lated splenic volume (expressed as percentage of baseline volume) using the
method of De Odorico [15].
Data quality. We audited the first 50 subjects (including both retrospective and
prospective subjects) to determine the rate of erroneous data. Erroneous data were
identified by a second review of all primary source data, and comparing with final
data in the registry. Erroneous data were defined as either an error in data coding
(i.e., the wrong value was recorded on the written CRF or transcribed onto the elec-
tronic CRF), or failure to use the data from the paper CRF.
We audited all 100 subjects to measure the rate of missing data, including the
rate of submission of CRFs as well as individual variables. We defined a CRF as
submitted if a CRF had at least one completed variable submitted for that time
point, and an individual variable as submitted if there were any data recorded for
that variable at that time point.
Data analysis. We summarized results into hematologic outcomes, short-term
AEs (30 days after surgery), and long-term AEs (31–365 days after surgery). This
structure was chosen to communicate important outcomes to all stakeholders,
including families [3]. We analyzed hematologic outcomes and AEs based on type
of disease (HS versus SCD) as well as by type of procedure (PS versus TS). Due to
small number of children with other types of CHA, detailed analysis of outcomes
was limited to children with HS or SCD.
We determined differences between cohorts using Pearson’s Chi squared or
Fisher’s exact test for categorical data, and Mann–Whitney U test, Kuskal-Wallis
rank sum test or Wilcoxon signed ranks test for continuous data, using a two-tailed
significance of 5%. Comparisons of preoperative and postoperative symptoms were
made using McNemar’s test for matched data. Categorical variables were expressed
as percentage, and continuous variables by median and interquartile range (IQR) or
mean6 standard deviation (SD). For hematologic data, we graphically described
trends of mean6 standard error (SE), and confirmed differences between baseline
and each time point by matched analysis of nonparametric continuous data using
the Wilcoxon signed ranks test, with analysis limited to children who had data at
baseline and at that time point. All analyses were performed using R version 3.0.2.
 Results
Demographics
As of November 2014, 134 children were enrolled in the registry
from 16 sites (mean 8.9 subjects/site, median 3 subjects/site),
although this report is limited to the first 100 children who reached
at least one year after surgery (Table I). There was an equal distribu-
tion of boys and girls, with expected racial and ethnic disparity by
disease type. Use of preoperative vaccines and postoperative antibiot-
ics was high. Most children had HS (n5 40) or SCD (n5 50), with
subtypes of SCD including hemoglobin SS (n5 30) or SC (n5 10).
Ten children had another type of CHA, including pyruvate kinase
deficiency (n5 1), alpha thalassemia/hemoglobin E-Constant Spring
(n5 3), beta thalassemia intermedia (n5 1), beta thalassemia major
(n5 1), hemoglobin CC (n5 1), hemoglobin Koln (n5 1), or CHA,
unspecified (n5 2).
The type of procedure differed by disease. For children with HS,
19/40 (48%) received a PS and 21/40 (52%) received TS. For children
with SCD, 34/50 (68%) received TS, and 16/50 (32%) received a PS.
The majority of children undergoing TS had an initial laparoscopic
approach (47/54, 87%). In contrast, only 12/46 (26%) of children
with PS had a laparoscopic approach, and 6/12 (50%) were converted
to laparotomy.
Hematologic outcomes
Hereditary spherocytosis. Most children with HS had resolution of
their clinical symptoms following TS or PS (Table II). For children
with HS, we found an increase in hemoglobin (baseline 10.16 1.8 g/dl,
4 week 12.76 1.5 g/dl, 24 week 13.46 2.1 g/dl, 52 week 12.86 1.6 g/dl;
mean6 SD), decrease in reticulocyte count (baseline 9.06 4.4%, 4
week 2.26 2.5%, 24 week 4.66 2.8%, 52 week 4.56 2.0%), and
decrease in bilirubin (baseline 3.06 1.4 mg/dl, 4 week 0.76 0.6 mg/dl,
24 week 1.06 0.6 mg/dl, 52 week 1.16 0.3 mg/dl) (Fig. 1A–C). By
matched analysis, the increase in hemoglobin was significant (P< 0.05)
at each time point compared with baseline. Both TS and PS led to an
increase in hemoglobin at all time points compared to baseline (Fig.
1A–C), although there was not adequate data to compare outcomes
between TS and PS.
Sickle cell disease. Children with SCD had resolution of their clin-
ical symptoms following TS or PS, including splenic sequestration or
participation in a regular transfusion program (Table II). In contrast
to children with HS, children with SCD had similar hemoglobin,
reticulocyte count, and serum bilirubin postoperatively compared to
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baseline (Fig. 2A–C). Both TS and PS resulted in similar hemoglobin
after surgery compared with baseline. The small number of children
with SCD precluded comparison of outcomes between TS and PS as
well as comparison of outcomes between hemoglobin SS and SC
disease.
Splenic growth and function following partial splenectomy. For all
35 children undergoing PS, the measured splenic volume was stable
over 1 year: (Fig. 3; baseline volume 4136 328 ml (100%); 4 week
586 66 ml (14%); 24 week 456 35 ml (10%); 52 week 636 42 ml
(12%); expressed as mean6 standard deviation (SD) and percentage
of baseline volume). No child required a completion splenectomy
during 1 year of follow-up. We were not able to analyze preservation
of splenic function following PS (i.e., nuclear medicine liver spleen
scans, Doppler splenic ultrasound, notations of Howell-Jolly bodies,
etc.), as these studies were not performed consistently across sites.
Adverse events
The overall rate of short-term AEs was 11%, with no death
recorded. For children with HS, there was a 2.5% rate of infection. In
children with SCD, there was a 10.0% rate of infection and 12.0%
rate of acute chest syndrome (ACS).
The overall rate of long-term AEs was also 11%, with no deaths
recorded. For children with HS, there were no infections or throm-
botic events, and one reoperation (3.1%) over 1 year of follow-up.
Children with SCD had a 14.3% rate of infection, including two with
sepsis, one with upper respiratory tract infection (URI), one with par-
ainfluenza, one with influenza B, and one unspecified. Children with
SCD had a 9% rate of ACS and a 2% rate of blood transfusion. There
was one child (2%) with a thrombotic event, who had a transient
ischemic attack 24 weeks after TS.
Data quality
Audit of the first 50 patients (24 retrospective, 26 prospective)
demonstrated 5 erroneous variables out of 4,873 entries (0.1%). All of
these were with data coding, i.e. the wrong value was recorded on the
CRF or transcribed onto the electronic CRF, with no failures to use
the data from the paper CRF. Of note, there were 8 children with HS
who were reported to have splenic sequestration, which likely reflects
an error in data coding.
Analysis of missing data showed that 92% (369 out of 400) of all
CRFs were completed. The rate of CRF completion was highest at
early time points: 100% at baseline, 96% at 4 weeks, 91% at 24 weeks,
and 82% at 52 weeks. Analysis of individual variables showed that
12,189 out of 16,400 (74.3%) were completed.
 Discussion
For children with CHA, the outcomes following TS or PS are
poorly defined, leaving families and clinicians in a quandary when
deciding between surgical therapies or surgical vs. medical therapies.
Most existing studies in this area are either single center or small
multicenter reports, and are limited by use of nonstandardized data
TABLE I. Demographics of Children With Congenital Hemolytic Anemia Undergoing Total Splenectomy or Partial Splenectomy
Overall Hereditary spherocytosis Sickle cell disease Other P-value
N 100 40 (40%) 50 (50%) 10 (10%)
Demographics
Gender 0.453
Male 49 (49%) 19 (47.5%) 27 (54%) 3 (30%)
Female 51 (51%) 21 (52.5%) 23 (46%) 7 (70%)
Race/Ethnicity < 0.001
White 35 (35%) 30 (75%) 0 (0%) 5 (50%)
Black 53 (53%) 6 (15%) 46 (92%) 1 (10%)
Hispanic 7 (7%) 3 (7.5%) 4 (8%) 0 (0%)
Other 5 (5%) 1 (2.5%) 0 (0%) 4 (40%)
Preoperative Vaccinations
Pneumovax 0.001
Yes/No or unknown 87/13 (87%) 34/6 (85%) 48/2 (96%) 5/5 (50%)
Meningovax or Menactra 0.001
Yes/No or unknown 80/20 (80%) 30/10 (75%) 46/4 (92%) 4/6 (40%)
Postoperative Antibiotics 0.348
Yes/No or unknown 98/1 (99%) 38/1 (97%) 50/0 (100%) 10/0 (100%)
Numbers represent counts (%) for each variable in the overall cohort and grouped by diagnosis. P-values represent Pearson’s Chi-square or Fisher’s exact
test as appropriate for a difference between the diagnostic groups.
TABLE II. Clinical Symptoms at Baseline and After Total Splenectomy or Partial Splenectomy for Children With Hereditary Spherocytosis or Sickle Cell
Disease
Hereditary spherocytosis Sickle cell disease
Baseline Postop P-value Baseline Postop P-value
Splenic sequestration 8 (20%) 1 (2.6%) 0.034 45 (90%) 1 (2.1%) <0.001
Transfusions 8 (20%) 0 (0%) 0.005 13 (26%) 1 (2%) <0.001
Aplastic or anemic crisis 5 (12.5%) NR NR NR
Hypersplenism 0 (0%) NR 4 (8%) NR
Splenomegaly 11 (27.5%) 0 (0%) <0.001 5 (10%) 0 (0%) 0.025
Numbers represent counts (%) for symptoms at baseline and postoperatively for children with hereditary spherocytosis or sickle cell disease following total
splenectomy or partial splenectomy. Transfusions-History of transfusions or participation in regular transfusion program. p-values represent McNemar’s for
matched pair differences between baseline and postoperative symptoms. Any symptom reported during 1 year follow-up was counted as having a postoper-
ative symptom, with multiple episodes during follow-up counted only once. NR-Not recorded
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(see review [3]). Furthermore, many of the studies in this area were
performed before the widespread use of Prevnar-13 [17], and the cur-
rent rate of infectious events following splenectomy is unknown. In
our current report from a patient registry of 100 children with CHA
undergoing TS or PS, we found that both procedures result in favor-
able clinical outcomes and have a low rate of AEs over 1 year of
follow-up. This observational study is the first multicenter report
using standardized data in this area, and should be of great value to
families and clinicians considering splenectomy.
The clinical outcomes of TS and PS differ between diseases. For
HS, all types of splenectomy resulted in control of clinical symptoms
as well as improvement in hematologic laboratory parameters.
Although our registry did not compare outcomes between PS and TS,
both procedures had improved hematologic outcomes after surgery, a
finding consistent with most previous literature [3,4,14,18,19]. A pro-
spective randomized clinical trial will be required to definitively com-
pare surgical procedures or surgical vs medical therapies. Finally,
although control of clinical symptoms of primary importance to fami-
lies, we suggest that future studies of splenectomy examine the spe-
cific goals of families and clinicians as they chose between surgical or
medical therapies, as well as assessment of satisfaction with the
outcomes.
Figure 1. A–C: Hematologic outcomes following partial splenectomy or
total splenectomy in 40 children with hereditary spherocytosis. Data rep-
resent hemoglobin (Panel A), reticulocyte count (Panel B) or serum biliru-
bin (Panel C) at baseline, and at 4, 24, or 52 weeks after partial
splenectomy (n5 19) or total splenectomy (n5 21). All data expressed as
mean, with error bars representing standard error. Data on hemoglobin
and bilirubin in TS group at 52 weeks had too few data entries to include
in the analysis.
Figure 2. A–C: Hematologic outcomes following partial splenectomy or
total splenectomy in 50 children with sickle cell disease. Data represent
hemoglobin (Panel A), reticulocyte count (Panel B) or serum bilirubin
(Panel C) at baseline, and at 4, 24, or 52 weeks surgery after partial sple-
nectomy (n5 16) or total splenectomy (n5 34). All data expressed as
mean, with error bars representing standard error.
Figure 3. Splenic volume in 35 children following partial splenectomy,
including 19 children with hereditary spherocytosis and 16 children with
sickle cell disease. Data represent mean splenic volume at each time point
measured by ultrasound as calculated using the method of De Odorico [15].
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For children with SCD, all types of splenectomy control clinical symp-
toms, particularly the need for transfusions, although there is no effect
on hemoglobin or other hematologic parameters. This finding is consist-
ent with most previous literature [20–22], although some single center
case series have shown improvement in hemoglobin levels [23,24]. Given
the heterogeneity of different types of SCD, a clinical trial will require a
large number of enrolled children to compare partial or total splenec-
tomy, as well as to define the optimal candidates for each procedure in
terms of use of hydroxyurea, age, and functional splenic status.
There is a low overall rate of AEs after PS or TS, although children
with SCD have continued risks of infection and ACS, which is likely
related to their underlying disease. In contrast to reports describing a
high rate of vascular thrombosis after splenectomy [25,26], we
recorded only one child with a thrombotic event, and this event likely
is attributable to SCD as it occurred 24 weeks following surgery.
However, as we collected only symptomatic thrombotic events over 1
year, the long-term risk of vascular complications may be greater
than those clinically evident. We also found that no children required
a completion splenectomy during the 1 year observation period, in
contrast to the 10–40% rate reported in small case series over several
years of follow-up [4,14,27,28].
We learned several lessons about a registry that are helpful for the
study of CHA. First, we recognized that early definition of important
issues for all stakeholders, including families, is essential. During pilot
testing we collected 110 variables and later realized that many did not
address important concerns and/or were not routinely tested. Using a
smaller data dictionary allowed for less site burden and improved
data quality. Second, optimal registry design using standardized data
is critical to maximize data quality. Our missing data rate is similar
to other large observational registries [29,30]. Although the use of a
protocol with required tests would minimize missing data, we caution
against mandating these practices for an observational pediatric regis-
try, as this may decrease the rate of enrollment [31].
We observed several findings in regards to variability of care.
Although this observational study was not designed to compare out-
comes between procedures or sites, we found a low rate of laparo-
scopy in children undergoing PS, which may be due to the complex
nature of laparoscopy for PS or reflect clinical care patterns which
are currently evolving towards increased use of laparoscopy. In con-
trast to PS, TS is generally performed laparoscopically, which is
attractive to families as laparoscopic splenectomy results in a shorter
length of stay and less morbidity than an open procedure [3]. How-
ever, if given a choice between a laparoscopic TS and an open PS, it
is unclear which families would prefer, as both options offer a differ-
ent set of benefits. Furthermore, even if family preference would drive
the choice towards a given procedure, is this optimal for a child?
Although these issues are beyond the scope of this current report, we
suggest that future study of splenectomy in CHA should address how
these issues affect the family decision-making process.
There are several limitations to our study. First, this report has
only one year of follow-up. However these findings should be of great
value to families and clinicians, as the rate of sepsis following sple-
nectomy is highest during the first year after surgery [32]. We do rec-
ognize that understanding the long-term outcomes (i.e., decades)
following TS or PS is critical to understand the role of surgery, and
plan to continue follow-up for several years after surgery. Second, as
an observational study, a registry does not allow for comparison of
surgical procedures or surgical versus medical therapies. Third, some
important outcomes such as splenic function following partial sple-
nectomy are difficult to assess though an observational study, as these
tests are not performed consistently across sites. Finally, our registry
used an informed consent process that may have skewed the results,
as the consent process may change enrollment from a population
based cohort to a selective cohort [33]. Although informed consent
traditionally has been fundamental to clinical research, some experts
suggest that the consent process for registries should be reassessed, as
the public health value of this information may outweigh the risks to
personal identity [33].
In conclusion, we found favorable clinical outcomes and a low rate
of AEs in children with CHA following PS or TS using a multicenter
patient registry. These findings demonstrate the great value as well as
the inherent limitations of a patient registry, and define expected out-
comes of these procedures. As we accumulate a greater number of
children in this registry, extend long-term follow-up, we should
enhance our understanding of these procedures, facilitate the design
of clinical trials, and engage all stakeholders in the decision-making
process when considering surgery.
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